Analysis Group Collaborates on Retrospective Study of Medication Adherence Among Adults with Metastatic Colorectal Cancer
September 28, 2018
Analysis Group client Taiho Oncology, Inc. announced real-world medication adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF® (trifluridine and tipiracil) or Stivarga® (regorafenib). The third most common type of cancer in the United States, excluding skin cancer, mCRC is also a leading cause of cancer-related deaths among both men and women.
Using data from the IQVIA™ Real-World Data Adjudicated Claims-US database, the retrospective study found that treatment with LONSURF® was associated with significantly higher medication adherence and longer time to discontinuation compared to treatment with regorafenib. The study was conducted by an Analysis Group team – including Managing Principal Mei Sheng Duh and Vice Presidents François Laliberté and Mihran Yenikomshian – in collaboration with Anuj Patel, MD, of Dana-Farber Cancer Institute. The study data was presented by Dr. Patel at the 2018 ASCO Quality of Care Symposium (ASCO QCS) on September 28, 2018.